You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

Displaying 1 - 10 of 8128 results
  1. Sequencing microRNAs, with single-base discrimination, using a nanopore device and an Osmium tag.

    SBC: YENOS ANALYTICAL LLC            Topic: 172

    PROJECT SUMMARY The goal of this work is to develop an inexpensive, ultra-fast, minimally-invasive medical test to sequence and quantitate small RNAs from biological fluids. Small RNAs, shorter than 200 nucleotides (nt) comprise several groups of non-coding RNAs with preserved regulatory functions. Small RNAs are abundant and surprisingly stable in blood/urine. Current literature is flooded with s ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Fast Large Area Multiphoton Exoscope (FLAME)

    SBC: InfraDerm, LLC            Topic: NIBIB

    Summary. Our long-term goal is to develop a powerful tool based on multiphoton microscopy (MPM) for non- invasive human skin imaging in order to improve clinical diagnosis, guide effective treatment and advance clinical and cosmetic/pharmaceutical research by providing access to dynamic cellular and molecular processes during therapy. MPM is a nonlinear optical imaging technique that provides uniq ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Selective actin remodeling of sensory neurons for acute pain management

    SBC: Neurocarrus Inc.            Topic: NINDS

    PROJECT SUMMARY There is an urgent need for new approaches to treat acute human pain without the risk of Substance Use Disorders (SUDs). The most effective approved pain pharmaceuticals, including narcotics and anesthetics, are not neuron-specific and consequently suffer from off-target effects like addiction, inhibition of motor neurons, and destruction of the surrounding tissues. When inflammati ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Development of KCC2 neuromodulators to treat paralysis after spinal cord injury.

    SBC: AXONIS THERAPEUTICS, INC.            Topic: 106

    Summary Roughly 17,000 people in the United States will suffer a spinal cord injury (SCI) this year. For the vast majority of them, the injury will leave them incapable of walking or, if they have suffered a cervical SCI, entirely dependent upon others for assistance in all of their activities of daily living from feeding to personal care. More importantly, chances of improvement as a result of th ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Development of PMP22 siRNA Conjugates for Treatment of Charcot-Marie-Tooth Disease Type 1A

    SBC: DTx Pharma, Inc.            Topic: NINDS

    PROJECT SUMMARY: Charcot-Marie-Tooth (CMT) disease is the most frequent inherited neuropathy affecting the peripheral nervous system and is characterized by a group of genetically and clinically heterogeneous disorders leading to progressive weakness and atrophy in distal muscles, sensory loss, hyporeflexia and skeletal deformity. CMT type 1A (CMT1A) is the most prevalent form, affecting 1 in 10,0 ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Care Improving Cognition for ADolescents on the Autism Spectrum (CICADAS)

    SBC: Posit Science Corporation            Topic: 104

    PROJECT SUMMARY The goal of the current project is to elaborate upon, reconstruct and advance to pivotal trial readiness CICADAS (Care Improving Cognition for ADolescents on the Autism Spectrum)—a clinician-assisted, closed-loop technology, mobile application for adolescents with Autism Spectrum Disorder (ASD). Via ten mobile assessments CICADAS will capture data on sensory processing abnormalit ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A youth-specific helmet for preventing traumatic brain injury

    SBC: SAVIOR BRAIN INC.            Topic: NINDS

    PROJECT SUMMARY Head injuries, including nearly 4 million concussions per year, are common among the nearly 40 million participants in organized youth sports in the United States. Despite recent technologies marketed to reduce concussion risk, head injuries continue to rise among youth athletes. Furthermore, studies to improve protective equipment have largely focused on adult populations, leading ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Developing Drug-like Small Molecules that Target Toxic Repeat RNAs to Alleviate Myotonic Dystrophy Type 1-derived Mis-Splicing

    SBC: Nymirum, Inc.            Topic: 104

    Project Summary Abstract Nymirum will utilize its technology platform to identify and optimize a drug-like, orally available small molecule that binds toxic CUG repeat RNAs to rescue myotonic dystrophy type 1 (DM1) derived mis-splicing and treat the disease. DM1 is a rare genetic disorder that leads to progressive muscle degeneration, cardiovascular disease, severe cognitive disabilities, insulin ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a topical fixed-dose combination drug for peripheral neuropathic pain.

    SBC: WinSanTor, Inc.            Topic: NINDS

    PROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. The top two major causes of peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents. Currently, there are no FDA-approved treatments to prevent or reverse ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a non-opioid chemogenetic therapy for chronic neuropathic pain

    SBC: CODA Biotherapeutics, Inc.            Topic: NINDS

    Project Summary/Abstract Current pharmacological and surgical treatments frequently fail to produce effective and/or durable neuropathic pain relief and are associated with severe side- or off-target effects. CODA Biotherapeutics is developing a powerful, targeted approach to treating chronic neuropathic pain that overcomes many conventional limitations. Our chemogenetic strategy is unique in that ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government